Effect of systemic administration of isotretinoin on blood lipids and fatty acids in acne patients.
BACKGROUND
In many studies, an increase in total cholesterol and triglycerides with isotretinoin therapy have been shown and investigators have commented on potential cardiovascular risk. A low intake of linoleic acid, the main essential fatty acid in man, may act as an independent risk factor for coronary heart disease. In vitro etretin alters both the incorporation of extracellular fatty acids into cell membranes and the fatty acid composition of the cell membrane itself. It is, therefore, important to establish whether isotetinoin has any effect on the metabolism of polyunsaturated fatty acids.


METHODS
The effect of treatment with isotretinoin for 4 months on the metabolism of polyunsaturated fatty acids in patients with acne was assessed. Quantitative total cholesterol and triglycerides as well as plasma phospholipid, triglycerides, and cholesteryl ester fatty acids were measured in 12 patients and red cell phosphatidylethanolamine, phosphatidylcholine, and phosphatidylinositol fatty acids were measured in 13 patients before and after isotretinoin therapy.


RESULTS
There was a significant increase in the concentrations of cholesterol (P < 0.02) and triglycerides (P < 0.04) during treatment. There was no significant difference is plasma phospholipids, triglycerides, and cholesterol esters, or in the red cell phosphatidylethanolamine, phosphatidylcholine, and phosphatidylinositol during isotretinoin therapy.


CONCLUSIONS
This study failed to demonstrate any effect of isotretinon on the metabolism of polyunsaturated fatty acids. There was a significant increase in total cholesterol and triglyceride levels following isotretinoin therapy supporting the findings of many previous studies.
Ostlere
L S
LS
Department of Dermatology, Royal Free Hospital, School of Medicine, London, England.
Harris
D
D
Morse-Fisher
N
N
Wright
S
S
D000152:Acne Vulgaris / Q000097:blood / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002784:Cholesterol / Q000097:blood; D005227:Fatty Acids / Q000097:blood; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects / Q000627:therapeutic use*; D007641:Keratolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D005227:Fatty Acids; D007641:Keratolytic Agents; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D015474:Isotretinoin